Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional MMR vaccine versus tuberculin PPD for palmoplantar and periungual warts
TCTR20200604014Phase 3Completed
- Sponsor
- Ramathibodi Hospital
- Start
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of measles, mumps, and rubella vaccine, tuberculin purified protein derivative in Palmoplantar wart, periungual wart, sponsored by Ramathibodi Hospital. Started Jun 2020; status: completed.
02
Drugs
measles, mumps, and rubella vaccinetuberculin purified protein derivative
03
Conditions
Palmoplantar wartperiungual wart
Beyond the preview
Go deeper on TCTR20200604014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20200604014.